

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 887 081 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

30.12.1998 Bulletin 1998/53

(51) Int Cl.⁶: **A61K 38/45, A61K 48/00,**

G01N 33/50

(21) Application number: **98304189.8**

(22) Date of filing: **27.05.1998**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **27.06.1997 US 51124 P**

(71) Applicant: **SMITHKLINE BEECHAM
CORPORATION**

Philadelphia Pennsylvania 19103 (US)

(72) Inventor: **Kumar, Janet M.**

King of Prussia, Pennsylvania 19406 (US)

(74) Representative:

Connell, Anthony Christopher et al

SmithKline Beecham plc

Corporate Intellectual Property,

Two New Horizons Court

Brentford, Middlesex TW8 9EP (GB)

(54) **Human serum glucocorticoid regulated kinase, a target for chronic renal disease**

(57) Disclosed are methods for utilizing human *sgk* polypeptides and polynucleotides in the design of pro-

tocols for the treatment of chronic renal failure and diabetic nephropathy, among others, and diagnostic assays for such conditions.

EP 0 887 081 A2

Description

FIELD OF INVENTION

The field of the invention is treatment of chronic renal failure and diabetic nephropathy.

BACKGROUND OF THE INVENTION

The serum glucocorticoid regulated kinase (*sgk*) was discovered in a rat mammary tumor cell line (Con8.hd6) to be a novel member of the serine/threonine protein kinase family whose expression is transcriptionally regulated by glucocorticoids and serum (Webster et al., 1993, Mol. Cell Biol. 13:2031-2041). It is expressed in other rat tissues such as the ovary, thymus and lung with lower levels in most other tissues (Webster et al., 1993, Mol. Cell Biol. 13:2031-2041). Sequence analysis of the full length rat *sgk* mRNA predicts a 431 amino acid protein of 49 kDa. The *sgk* protein contains a putative 270 amino acid catalytic domain made up of 11 distinct subdomains, one of which suggests phosphorylation of serine/threonine substrates. *Sgk* shares sequence homology with other kinases in this region. These include the human rac a, rat protein kinase C-b, rat ribosomal protein S6 kinase and the mouse cyclic AMP dependent protein kinase. Despite the homology with other kinases, *sgk* has yet to be shown to be a functional kinase.

The promoter region of the rat *sgk* gene contains a functional glucocorticoid responsive element (GRE) and the induction of *sgk* appears to be a glucocorticoid receptor-specific response (Webster et al., 1993, Mol. Cell Biol. 13:2031-2041). A similar increase in *sgk* transcript levels is observed in rat mammary tumor cells after treatment with either dexamethisone, hydrocortisone or corticosterone all of which use the glucocorticoid receptor pathway whereas steroids which have an alternate means of gene activation such as cholesterol, progesterone, β -estradiol, and testosterone were unable to induce *sgk* mRNA expression (Webster et al., 1993, Mol. Cell Biol. 13:2031-2041). Serum also stimulates *sgk* mRNA expression in these cells although the pathway of activation is unclear. Recently, p53, a tumor suppressor protein, has been found to repress *sgk* promoter activity (Maiyar et al., 1997, Mol. Endocrin. 11:312-329). This represents the first example of a hormone regulated kinase gene regulated by p53 (Maiyar et al., 1996, J. Biol. Chem. 271:12414-12422).

The function of *sgk* in the cell is unclear. In some cell types *sgk* may play a role in cell growth. In the Con8.hd6 cells, glucocorticoid treatment, which increases *sgk* expression, decreases the proliferation. However, in other cell lines dexamethisone increases *sgk* levels without affecting cell growth. Some data suggests that it may play a role in mitogenic response in the G₀-G₁ transition in quiescent Rat2 fibroblasts since it is induced in response to serum stimulation and has a rapid half life like other immediate-early response genes (Webster et al., 1993, J. Biol. Chem. 268:11482-11485). One group proposes that *sgk* is involved in wound healing and regeneration in the central nervous system. *Sgk* was found to be strongly expressed in glial cells and oligodendrocytes surrounding lesions in the injured rat brain (Imaizumi et al., 1994, Mol. Brain Res. 26:189-196). Recently, *sgk* transcript levels were found to be influenced by alterations in anisotonic and isotonic conditions indicating that it may play a role in cellular response to cell volume (Waldegger et al., 1997, Proc. Natl. Acad. Sci. 94:4440-4445). Whatever its role, *sgk* is most likely involved in a complex series of phosphorylations/dephosphorylations regulated separately and/or concurrently by a number of extracellular and intracellular factors such as glucocorticoids, serum, growth factors and p53.

A number of animal model systems have been studied to provide clues as to the cause(s) of renal failure. Molecules whose expression is either increased or decreased in the diseased kidney of these model systems may be important mediators of kidney failure. Differential display PCR was performed to identify such genes in the kidneys of lean and obese db/db mice. One of the genes increased in obese mouse kidney was found to be a 500 base pair cDNA 91% identical with the rat *sgk*. Northern analysis demonstrated that *sgk* mRNA levels were increased 5 fold in the kidney of diabetic obese mice as compared to lean littermates. Of the other tissues examined, heart, brain and liver, *sgk* mRNA levels were similar between lean and obese mice. Thus, *sgk* induction is kidney specific. Further analysis indicated that *sgk* mRNA expression was also increased 2 fold in the kidney of diabetic humans as compared to control kidneys. This is the first demonstration that *sgk* may be involved in a diseased state, namely renal disease.

There remains a need for compositions for treatment of chronic renal disease which serve to diminish or ablate disease leading to renal failure and either death or dependence on dialysis.

SUMMARY OF THE INVENTION

The invention relates to methods to identify agonists and antagonists of human *sgk* and treating conditions associated with *sgk* imbalance with the identified compounds.

DESCRIPTION OF THE INVENTION

Definitions

5 The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"Human *sgk*" or "human *sgk* polypeptide" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.

10 "Human *sgk* activity or human *sgk* polypeptide activity" or "biological activity of the human *sgk* or human *sgk* polypeptide" refers to the metabolic or physiologic function of said human *sgk* including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said human *sgk*.

"Human *sgk* gene" refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO:1 or allelic variants thereof and/or their complements.

15 "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

20 "Polynucleotide" generally refers to any polyribonucleotide or polydeoxynucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes 25 DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

30 "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of 40 modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62.

55 "Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not

alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., *et al.*, *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. *et al.*, *J Molec Biol* (1990) 215:403).

"Chronic renal failure" is the progressive loss of functional renal mass, accompanied by compensatory growth and remodeling. The molecular and cellular events that take place during chronic renal failure include release of growth factors, proliferation of glomerular mesangial cells and expansion of extracellular matrix (Klahr *et al.*, 1988, *New Engl. J. Med* 318:1657-1666; Striker *et al.*, 1989, in: Klahr, (Ed.) *Seminars in Nephrology*, pp. 318, Philadelphia, (W.B. Saunders); Ebihara *et al.*, 1993, *J. Am. Soc. Nephrol.* 3:1387-1397).

Table 1^a

5	GGCACGAGGG AGCGCTAACG TCTTTCTGTC TCCCCGCGGT GGTG ATG ACG GTG AAA 56	Met Thr Val Lys
10	ACT GAG GCT GCT AAG GGC ACC CTC ACT TAC TCC AGG ATG AGG GGC ATG 104	Thr Glu Ala Ala Lys Gly Thr Leu Thr Tyr Ser Arg Met Arg Gly Met
	GTG GCA ATT CTC ATC GCT TTC ATG AAG CAG AGG AGG ATG GGT CTG AAC 152	Val Ala Ile Leu Ile Ala Phe Met Lys Gln Arg Arg Met Gly Leu Asn
15	GAC TTT ATT CAG AAG ATT GCC AAT AAC TCC TAT GCA TGC AAA CAC CCT 200	Asp Phe Ile Gln Lys Ile Ala Asn Asn Ser Tyr Ala Cys Lys His Pro
	GAA GTT CAG TCC ATC TTG AAG ATC TCC CAA CCT CAG GAG CCT GAG CTT 248	Glu Val Gln Ser Ile Leu Lys Ile Ser Gln Pro Gln Glu Pro Glu Leu
20	ATG AAT GCC AAC CCT TCT CCT CCA CCA AGT CCT TCT CAG CAA ATC AAC 296	Met Asn Ala Asn Pro Ser Pro Pro Pro Ser Pro Ser Gln Gln Ile Asn
	CTT GGC CCG TCG TCC AAT CCT CAT GCT AAA CCA TCT GAC TTT CAC TTC 344	Leu Gly Pro Ser Ser Asn Pro His Ala Lys Pro Ser Asp Phe His Phe
25	TTG AAA GTG ATC GGA AAG GGC AGT TTT GGA AAG GTT CTT CTA GCA AGA 392	Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Lys Val Leu Leu Ala Arg
30	CAC AAG GCA GAA GAA GTG TTC TAT GCA GTC AAA GTT TTA CAG AAG AAA 440	His Lys Ala Glu Glu Val Phe Tyr Ala Val Lys Val Leu Gln Lys Lys
	GCA ATC CTG AAA AAG AAA GAG GAG AAG CAT ATT ATG TCG GAG CGG AAT 488	Ala Ile Leu Lys Lys Lys Glu Glu Lys His Ile Met Ser Glu Arg Asn
35	GTT CTG TTG AAG AAT GTG AAG CAC CCT TTC CTG GTG GGC CTT CAC TTC 536	Val Leu Leu Lys Asn Val Lys His Pro Phe Leu Val Gly Leu His Phe
	TCT TTC CAG ACT GCT GAC AAA TTG TAC TTT GTC CTA GAC TAC ATT AAT 584	Ser Phe Gln Thr Ala Asp Lys Leu Tyr Phe Val Leu Asp Tyr Ile Asn
40	GGT GGA GAG TTG TTC TAC CAT CTC CAG AGG GAA CGC TGC TTC CTG GAA 632	Gly Gly Glu Leu Phe Tyr His Leu Gln Arg Glu Arg Cys Phe Leu Glu
	CCA CGG GCT CGT TTC TAT GCT GCT GAA ATA GCC AGT GCC TTG GGC TAC 680	

EP 0 887 081 A2

	Pro	Arg	Ala	Arg	Phe	Tyr	Ala	Ala	Glu	Ile	Ala	Ser	Ala	Leu	Gly	Tyr	
																	212
5	CTG	CAT	TCA	CTG	AAC	ATC	GTT	TAT	AGA	GAC	TTA	AAA	CCA	GAG	AAT	ATT	728
	Leu	His	Ser	Leu	Asn	Ile	Val	Tyr	Arg	Asp	Leu	Lys	Pro	Glu	Asn	Ile	
																	228
	TTG	CTA	GAT	TCA	CAG	GGA	CAC	ATT	GTC	CTT	ACT	GAC	TTC	GGA	CTC	TGC	776
	Leu	Leu	Asp	Ser	Gln	Gly	His	Ile	Val	Leu	Thr	Asp	Phe	Gly	Leu	Cys	
																	244
10	AAG	GAG	AAC	ATT	GAA	CAC	AAC	AGC	ACA	ACA	TCC	ACC	TTC	TGT	GGC	ACG	824
	Lys	Glu	Asn	Ile	Glu	His	Asn	Ser	Thr	Thr	Ser	Thr	Phe	Cys	Gly	Thr	
																	260
	CCG	GAG	TAT	CTC	GCA	CCT	GAG	GTG	CTT	CAT	AAG	CAG	CCT	TAT	GAC	AGG	872
	Pro	Glu	Tyr	Leu	Ala	Pro	Glu	Val	Leu	His	Lys	Gln	Pro	Tyr	Asp	Arg	
15																	276
	ACT	GTG	GAC	TGG	TGG	TGC	CTG	GGA	GCT	GTC	TTG	TAT	GAG	ATG	CTG	TAT	920
	Thr	Val	Asp	Trp	Trp	Cys	Leu	Gly	Ala	Val	Leu	Tyr	Glu	Met	Leu	Tyr	
																	292
	GGC	CTG	CCG	CCT	TTT	TAT	AGC	CGA	AAC	ACA	GCT	GAA	ATG	TAC	GAC	AAC	968
20	Gly	Leu	Pro	Pro	Phe	Tyr	Ser	Arg	Asn	Thr	Ala	Glu	Met	Tyr	Asp	Asn	
																	308
	ATT	CTG	AAC	AAG	CCT	CTC	CAG	CTG	AAA	CCA	AAT	ATT	ACA	AAT	TCC	GCA	1016
	Ile	Leu	Asn	Lys	Pro	Leu	Gln	Leu	Lys	Pro	Asn	Ile	Thr	Asn	Ser	Ala	
																	324
25	AGA	CAC	CTC	CTG	GAG	GGC	CTC	CTG	CAG	AAG	GAC	AGG	ACA	AAG	CGG	CTC	1064
	Arg	His	Leu	Leu	Glu	Gly	Leu	Leu	Gln	Lys	Asp	Arg	Thr	Lys	Arg	Leu	
																	340
	GGG	GCC	AAG	GAT	GAC	TTC	ATG	GAG	ATT	AAG	AGT	CAT	GTC	TTC	TTC	TCC	1112
	Gly	Ala	Lys	Asp	Asp	Phe	Met	Glu	Ile	Lys	Ser	His	Val	Phe	Phe	Ser	
																	356
30	TTA	ATT	AAC	TGG	GAT	GAT	CTC	ATT	AAT	AAG	AAG	ATT	ACT	CCC	CCT	TTT	1160
	Leu	Ile	Asn	Trp	Asp	Asp	Leu	Ile	Asn	Lys	Lys	Ile	Thr	Pro	Pro	Phe	
																	372
	AAC	CCA	AAT	GTG	AGT	GGG	CCC	AAC	GAG	CTA	CGG	CAC	TTT	GAC	CCC	GAG	1208
35	Asn	Pro	Asn	Val	Ser	Gly	Pro	Asn	Asp	Leu	Arg	His	Phe	Asp	Pro	Glu	
																	388
	TTT	ACC	GAA	GAG	CCT	GTC	CCC	AAC	TCC	ATT	GGC	AAG	TCC	CCT	GAC	AGC	1256
	Phe	Thr	Glu	Glu	Pro	Val	Pro	Asn	Ser	Ile	Gly	Lys	Ser	Pro	Asp	Ser	
																	404
40	GTC	CTC	GTC	ACA	GCC	AGC	GTC	AAG	GAA	GCT	GCC	GAG	GCT	TTC	CTA	GGG	1304
	Val	Leu	Val	Thr	Ala	Ser	Val	Lys	Glu	Ala	Ala	Glu	Ala	Phe	Leu	Gly	
																	420
	TTT	TCC	TAT	GCG	CCT	CCC	ACG	GAC	TCT	TTC	CTC	TGA					1340
	Phe	Ser	Tyr	Ala	Pro	Pro	Thr	Asp	Ser	Phe	Leu						
																	431
45	ACCCTGTTAG	GGCTTGGTTT	TAAAGGATT	TATGTGTGTT	TCCGAATGTT												1390
	TTAGTTAGCC	TTTTGGTGGA	GCCGCCAGCT	GACAGGACAT	CTTACAAGAG												1440
	AATTTGCACA	TCTCTGGAAG	CTTAGCAATC	TTATTGCACA	CTGTTGCTG												1490
50	GAAGCTTTTT	GAAGAGCACA	TTCTCCTCAG	TGAGCTCATG	AGGTTTTTCAT												1540
	TTTTTATTCT	TCCTTCCAAC	GTGGTGCTAT	CTCTGAAACG	AGCGTTAGAG												1590
	TGCCGCTTA	GACGGAGGCA	GGAGTTTCGT	TAGAAAGCGG	ACGCTGTTCT												1640
	AAAAAAGGTC	TCCTGCAGAT	CTGTCTGGGC	TGTGATGACG	AATATTATGA												1690
55	AATGTGCCTT	TTCTGAAGAG	ATTGTGTTAG	CTCCAAAGCT	TTTCTATCG												1740

	CAGTGTTC	CA GTTCTTTATT	TTCCCTTG	TG GATATGCTGT	GTGAACCGTC	1790
	GTGTGAGT	GT GGTATGCCTG	ATCACAGAT	GATTTTGTTA	TAAGCATCAA	1840
5	TGTGACACT	TT GCAGGACACT	ACAACGTGGG	ACATTGTTTG	TTTCTTCCAT	1890
	ATTTGGAAGA	TAAATTTATG	TGTAGACTTT	TTTGTAAGAT	ACGGTTAATA	1940
	ACTAAAATTT	ATTGAAATGG	TCTTGCAATG	ACTCGTATTC	AGATGCCTAA	1990
10	AGAAAGCATT	GCTGCTACAA	ATATTTCTAT	TTTTAGAAAG	GGTTTTTATG	2040
	GACCAATGCC	CCAGTTGTCA	GTCAGAGCCG	TGGTGTTTTT	TCATTGTTTA	2090
	AAATGTCACC	TGTAAAATGG	GCATTATTTA	TGTTTTTTTT	TTTGCATTCC	2140
15	TGATAATGT	ATGTATTGTA	TAAAGAACGT	CTGTACATTG	GGTTATAACA	2190
	CTAGTATATT	TAAACTTACA	GGCTTATTTG	TAATGTAAAC	CACCATTTTA	2240
	ATGTACTGTA	ATTAACATGG	TTATAATACG	TACAATCCTT	CCCTCATCCC	2290
20	ATCACACAAC	TTTTTTTGTG	TGTGATAAAC	TGATTTTGGT	TTGCAATAAA	2340
	ACCCTG					

^a Nucleotide and deduced amino acid sequence from a human *sgk*. SEQ ID NOS: 1 and 2, respectively.

Screening Assays

The human *sgk* polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the human *sgk* polypeptide of the present invention. Thus, human *sgk* polypeptide may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These agonists or antagonists may be natural substrates, ligands, receptors, etc., as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991).

Human *sgk* polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate human *sgk* polypeptide on the one hand and which can inhibit the function of human *sgk* polypeptide on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as chronic renal failure, diabetic nephropathy, inflammation, Alzheimers disease, and wound healing. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as chronic renal failure, diabetic nephropathy, inflammation, Alzheimers disease, and wound healing.

In general, such screening procedures may involve using appropriate cells which express the human *sgk* polypeptide or respond to human *sgk* polypeptide of the present invention. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. Cells which express the human *sgk* polypeptide (or cell membrane containing the expressed polypeptide) or respond to human *sgk* polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted for human *sgk* activity.

The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the human *sgk* polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the human *sgk* polypeptide, using detection systems appropriate to the cells bearing the human *sgk* polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.

The human *sgk* cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of human *sgk* mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of human *sgk* polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit

or enhance the production of human sgk (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The human sgk polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the human sgk is labeled with a radioactive isotope (eg 125I), chemically modified (eg biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. In addition to being used for purification and cloning of the receptor, these binding assays can be used to identify agonists and antagonists of human sgk which compete with the binding of human sgk to its receptors, if any. Standard methods for conducting screening assays are well understood in the art.

Examples of potential human sgk polypeptide antagonists include peptides comprising specific portions of human sgk; peptidomimetics having anti-sgk activity; antibodies; or in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, etc., as the case may be, of the human sgk polypeptide, e.g., a fragment of the ligands, substrates, receptors; or small chemical molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

The human sgk can be made by a variety of recombinant genetic engineering techniques. The isolated nucleic acids, particularly the DNAs can be introduced into expression vectors by operatively linking the DNA to the necessary expression control regions (e.g. regulatory regions) required for gene expression. The vectors can be introduced into the appropriate host cells such as prokaryotic (e.g. bacterial), or eukaryotic (e.g. yeast or mammalian) cells by methods well known in the art (Ausubel et al., *supra*). The coding sequences for the desired proteins having been prepared or isolated, can be cloned into any suitable vector or replicon. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. The gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and optionally, an operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction. The coding sequence may or may not contain a signal peptide or leader sequence. The subunit antigens of the present invention can be expressed using, for example, the *E. coli* lac promoter or the protein A gene (*spa*) promoter and signal sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397.

In addition to control sequences, it may be desirable to add regulatory sequences with allow for regulation of the expression of the protein sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.

An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequences with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e. RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence). Modification of the sequences encoding the particular protein of interest may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame. The control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a cloning vector. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.

In some cases, it may be desirable to add sequences which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal. Alternatively, gene fusions may be created whereby the gene encoding the binding protein of interest is fused to a gene encoding a protein with other desirable properties. For example, a fusion partner could provide known assayable activity (e.g. enzymatic) which could be used as an alternative means of selecting the binding protein. The fusion partner could be a structural element, such as a cell surface element such that the binding protein (a normally cytosolic component) could be displayed on the cell surface in the form of a fusion protein. The fusion protein (e.g., fused to a FLAG peptide) is engineered to allow for purification of the expressed protein after host cell expression. It may also be desirable to produce mutants or analogs of the protein of interest. Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site directed mutagenesis and the formation of fusion proteins, are well known to those skilled in the art. See, e.g. T. Maniatis et al., *supra*; DNA Cloning, Vols. I and II, *supra*; Nucleic Acid Hybridization, *supra*.

A number of prokaryotic expression vectors are known in the art. See, e.g., U.S. Patent Nos. 4,578,355; 4,440,859; 4,436,815; 4,431,740; 4,431,739; 4,428,941; 4,425,437; 4,418,149; 4,411,994; 4,366,246; 4,342,832; see also U.K. Pat-

ent Applications GB 2,121,054; GB 2,008,123; GB 2,007,675; and European Patent Application 103,395. Yeast expression vectors are also known in the art. See, e.g., U.S. Patent Nos. 4,446,235; 4,443,539; 4,430,428; see also European Patent Applications, 103,409; 100,561; 96,491. pSV2neo (as described in J. Mol. Appl. Genet. 1;327-341) which uses the SV40 late promoter to drive expression in mammalian cells or pCDNA1neo, a vector derived from pcDNA1 (Mol. Cell Biol. 7:4125-29) which uses the CMV promoter to drive expression. Both these latter two vectors can be employed for transient or stable (e.g. using G418 or hygromycin resistance) expression in mammalian cells. Insect cell expression systems, e.g., *Drosophila*, are also useful, see for example, PCT applications US 89/05155 and US 91/06838 as well as EP applications 88/304093.3 and Baculovirus expression systems.

Depending on the expression system and host selected, the proteins of the present invention are produced by growing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed. The protein is then isolated from the host cells and purified. If the expression system secretes the protein into growth media, the protein can be purified directly from the media. If the protein is not secreted, it is isolated from cell lysates or recovered from the cell membrane fraction. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.

The knowledge that the human *sgk* may encode a protein kinase suggests that recombinant forms, described above, can be used to establish a protein kinase activity. Typically this would involve the direct incubation of purified human *sgk* with a protein or peptide substrate in the presence of γ -32P-ATP, followed by the measurement of radioactivity incorporated into the substrate by separation and counting. Separation methods include immunoprecipitation, conjugation of substrate to a bead allowing separation by centrifugation or determination of incorporation by scintillation proximity assay, SDS-PAGE followed by autoradiography or biosensor analysis. While the specific substrates are not yet known, candidates include human *sgk* itself (autophosphorylation), myelin basic protein, casein, histone and HSP27. Other substances might be discovered by incubating human *sgk* with random peptides conjugated to solid supports or displayed on the surface of phage or by incubation of human *sgk* with mammalian cell lysates and γ -32P-ATP, followed by separation of the labelled target proteins, and sequencing. The protein kinase activity of human *sgk* may require incubation with a specific upstream effector. This may be achieved by preincubating human *sgk* with lysates from a variety of stimulated eukaryotic cells and ATP.

This invention contemplates the treatment and/or amelioration of such diseases by administering an human *sgk* inhibiting amount of a compound. Without wishing to be bound by any particular theory of the functioning of the human *sgk* of this invention, it is believed that among the useful inhibitors of human *sgk* function are those compounds which inhibit the kinase activity of the human *sgk*. Other sites of inhibition are, of course, possible owing to its position in a signal transduction cascade. Therefore, inhibiting the interaction of human *sgk* with one or more of its upstream or downstream modulators/substrates is also contemplated by this invention. Inhibitors of protein-protein interactions between human *sgk* and other factors could lead to the development of pharmaceutical agents for the modulation of human *sgk* activity.

In one specific embodiment, a method to identify possible inhibitors of the *sgk* is described here. The peptide substrate of *sgk* will be biotinylated at one end. It will then be added to a 96 well streptavidin coated flash plate. The high affinity binding of the biotin to streptavidin in the wells will anchor the peptide in the well and allow the residues to be accessible for phosphorylation. Purified active *sgk*, 33 P- γ -ATP and compounds will then be incubated with the peptide at a suitable temperature for kinase activity to occur. The plates will be washed and the amount of phosphorylated peptide will be determined. Those wells with the least amount of radioactivity could contain a possible inhibitor.

Human *sgk* binding molecules and assays

Human *sgk* could be used to isolate proteins which interact with it and this interaction could be a target for interference. Inhibitors of protein-protein interactions between human *sgk* and other factors could lead to the development of pharmaceutical agents for the modulation of human *sgk* activity. As used herein, the term "modulate" refer to affecting the human *sgk* function.

Thus, this invention also provides a method for identification of binding molecules to human *sgk*. Genes encoding proteins for binding molecules to human *sgk* can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Such methods are described in many laboratory manuals such as, for instance, Coligan et al., Current Protocols in Immunology 1 (Rivett, A.J. Biochem. J. 291:1-10 (1993)): Chapter 5 (1991).

For example, the yeast two-hybrid system provides methods for detecting the interaction between a first test protein and a second test protein, in vivo, using reconstitution of the activity of a transcriptional activator. The method is disclosed in U.S. Patent No. 5,283,173; reagents are available from Clontech and Stratagene. Briefly, human *sgk* cDNA is fused to a Gal4 transcription factor DNA binding domain and expressed in yeast cells. cDNA library members obtained from cells of interest are fused to a transactivation domain of Gal4. cDNA clones which express proteins which can interact with human *sgk* will lead to reconstitution of Gal4 activity and transactivation of expression of a

reporter gene such as Ga11-1acZ. The sgk cDNA which is fused to the Ga14 transcription factor DNA binding domain may be mutated in one or more amino acids, method of which is described above, to enhance interaction of kinase with substrate.

An alternative method is screening of λ gt11, λ ZAP (Stratagene) or equivalent cDNA expression libraries with recombinant human sgk. Recombinant human sgk protein or fragments thereof are fused to small peptide tags such as FLAG, HSV or GST. The peptide tags can possess convenient phosphorylation sites for a kinase such as heart muscle creatine kinase or they can be biotinylated. Recombinant human sgk can be phosphorylated with 32 P or used unlabeled and detected with streptavidin or antibodies against the tags. λ gt11cDNA expression libraries are made from cells of interest and are incubated with the recombinant human sgk, washed and cDNA clones isolated which interact with human sgk. See, e.g., T. Maniatis et al, *supra*.

Another method is the screening of a mammalian expression library in which the cDNAs are cloned into a vector between a mammalian promoter and polyadenylation site and transiently transfected in COS or 293 cells followed by detection of the binding protein 48 hours later by incubation of fixed and washed cells with a labelled human sgk, preferably iodinated, and detection of bound human sgk by autoradiography. See Sims et al., *Science* 241:585-589 (1988) and McMahan et al., *EMBO J.* 10:2821-2832 (1991). In this manner pools of cDNAs containing the cDNA encoding the binding protein of interest can be selected and the cDNA of interest can be isolated by further subdivision of each pool followed by cycles of transient transfection, binding and autoradiography. Alternatively, the cDNA of interest can be isolated by transfecting the entire cDNA library into mammalian cells and panning the cells on a dish containing human sgk bound to the plate. Cells which attach after washing are lysed and the plasmid DNA isolated, amplified in bacteria, and the cycle of transfection and panning repeated until a single cDNA clone is obtained. See Seed et al, *Proc. Natl. Acad. Sci. USA* 84:3365 (1987) and Aruffo et al., *EMBO J.* 6:3313 (1987). If the binding protein is secreted, its cDNA can be obtained by a similar pooling strategy once a binding or neutralizing assay has been established for assaying supernatants from transiently transfected cells. General methods for screening supernatants are disclosed in Wong et al., *Science* 228:810-815 (1985).

Another alternative method is isolation of proteins interacting with human sgk directly from cells. Fusion proteins of human sgk with GST or small peptide tags are made and immobilized on beads. Biosynthetically labeled or unlabeled protein extracts from the cells of interest are prepared, incubated with the beads and washed with buffer. Proteins interacting with human sgk are eluted specifically from the beads and analyzed by SDS-PAGE. Binding partner primary amino acid sequence data are obtained by microsequencing. Optionally, the cells can be treated with agents that induce a functional response such as tyrosine phosphorylation of cellular proteins. An example of such an agent would be a growth factor or cytokine such as interleukin-2.

Another alternative method is immunoaffinity purification. Recombinant human sgk is incubated with labeled or unlabeled cell extracts and immunoprecipitated with anti-human sgk antibodies. The immunoprecipitate is recovered with protein A-Sepharose and analyzed by SDS-PAGE. Unlabelled proteins are labeled by biotinylation and detected on SDS gels with streptavidin. Binding partner proteins are analyzed by microsequencing. Further, standard biochemical purification steps known to those skilled in the art may be used prior to microsequencing.

Yet another alternative method is screening of peptide libraries for binding partners. Recombinant tagged or labeled human sgk is used to select peptides from a peptide or phosphopeptide library which interact with human sgk. Sequencing of the peptides leads to identification of consensus peptide sequences which might be found in interacting proteins.

human sgk binding partners identified by any of these methods or other methods which would be known to those of ordinary skill in the art as well as those putative binding partners discussed above can be used in the assay method of the invention. Assaying for the presence of human sgk/binding partner complex are accomplished by, for example, the yeast two-hybrid system, ELISA or immunoassays using antibodies specific for the complex. In the presence of test substances (i.e. inhibitors or antagonists) which interrupt or inhibit formation of human sgk/binding partner interaction, a decreased amount of complex will be determined relative to a control lacking the test substance.

Assays for free human sgk or binding partner are accomplished by, for example, ELISA or immunoassay using specific antibodies or by incubation of radiolabeled human sgk with cells or cell membranes followed by centrifugation or filter separation steps. In the presence of test substances which interrupt or inhibit formation of human sgk/binding partner interaction (i.e. inhibitors or antagonists), an increased amount of free human sgk or free binding partner will be determined relative to a control lacking the test substance.

Polypeptides of the invention also can be used to assess human sgk binding capacity of human sgk binding molecules in cells or in cell-free preparations.

Prophylactic and Therapeutic Methods

This invention provides methods of treating abnormal conditions such as, chronic renal failure, diabetic nephropathy, inflammation, Alzheimers disease, and wound healing, related to both an excess of and insufficient amounts of

human sgk polypeptide activity.

If the activity of human sgk polypeptide is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the human sgk polypeptide, such as, for example, by blocking the binding of ligands, substrates, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.

In another approach, soluble forms of human sgk polypeptides still capable of binding the ligand in competition with endogenous human sgk polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the human sgk polypeptide.

In still another approach, expression of the gene encoding endogenous human sgk polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, *J Neurochem* (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073; Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360. These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

For treating abnormal conditions related to an under-expression of human sgk and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates human sgk polypeptide, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of human sgk by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic-based Therapeutic Approaches*, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of human sgk polypeptides in combination with a suitable pharmaceutical carrier.

Formulation and Administration

Peptides, such as the soluble form of human sgk polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Examples

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.

Example 1

Sgk mRNA levels are increased in the kidney of a chronic renal failure mouse model. This is shown by a northern blot with 15 ug of total RNA extracted from the kidneys of lean and diabetic db/db mice and probed with a 500 base pair 32P labeled cDNA encoding the mouse sgk. The message specific for sgk is 2.4 kilobases (kb) and is induced 5-6 fold in the kidneys of the diabetic mice as compared to lean mice.

Example 2

The increased expression of sgk in the kidney of the diabetic mice is specific for the kidney. This is indicated by a northern blot with 10 ug of total RNA extracted from the liver, brain, heart and kidney of lean and diabetic db/db mice. The 2.4 kb sgk message is expressed in the brain, heart and kidney but not in the liver of these animals. However, sgk mRNA is only induced in the kidneys of the diabetic animals as compared to the lean animals and not in the other tissues.

Example 3

Not only is sgk message induced in a rodent renal failure model but its levels are increased in human diseased kidneys as well. A northern blot with 15 ug of total RNA extracted from the kidney of normal and diabetic patients was probed with a 500 base pair 32P labeled cDNA encoding the mouse sgk. The 2.4 kb sgk mRNA is induced 2 - 3 fold in the diabetic kidney as compared to the normal kidney.

Annex to the description

SEQUENCE LISTING.

5

(1) GENERAL INFORMATION

10

(i) APPLICANT: SmithKline Beecham Corporation

15

(ii) TITLE OF THE INVENTION: Human Serum Glucocorticoid
Regulated Kinase, A Target For Chronic Renal Disease

(iii) NUMBER OF SEQUENCES: 2

20

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SmithKline Beecham, Corporate Intellectual
Property

25

(B) STREET: Two New Horizons Court

(C) CITY: Brentford

(D) STATE: Middlesex

30

(E) COUNTRY: United Kingdom

(F) ZIP: TW8 9EP

35

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

40

(D) SOFTWARE: FastSEQ for Windows Version 2.0

45

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: Unknown

(B) FILING DATE: Herewith

(C) CLASSIFICATION:

50

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 60/051,124

(B) FILING DATE: 27-JUN-1997

55

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: CONNELL, Anthony Christopher
 (B) REGISTRATION NUMBER: 5630
 (C) REFERENCE/DOCKET NUMBER: GP50002

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: +44 1279 644 395
 (B) TELEFAX: +44 181 975 6294
 (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2346 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCACGAGGG AGCGCTAACG TCTTTCTGTC TCCCCGCGGT GGTGATGACG GTGAAAACTG	60
AGGCTGCTAA GGGCACCTC ACTTACTCCA GGATGAGGGG CATGGTGGCA ATTCTCATCG	120
CTTTCATGAA GCAGAGGAGG ATGGGTCTGA ACGACTTTAT TCAGAAGATT GCCAATAACT	180
CCTATGCATG CAAACACCCT GAAGTTCAGT CCATCTTGAA GATCTCCCAA CCTCAGGAGC	240
CTGAGCTTAT GAATGCCAAC CCTTCTCCTC CACCAAGTCC TTCTCAGCAA ATCAACCTTG	300
GCCCGTCGTC CAATCCTCAT GCTAAACCAT CTGACTTTCA CTTCTTGAAA GTGATCGGAA	360
AGGGCAGTTT TGGAAAGGTT CTTCTAGCAA GACACAAGGC AGAAGAAGTG TTCTATGCAG	420
TCAAAGTTTT ACAGAAGAAA GCAATCCTGA AAAAGAAAGA GGAGAAGCAT ATTATGTCGG	480
AGCGGAATGT TCTGTTGAAG AATGTGAAGC ACCCTTTCCT GGTGGGCCTT CACTTCTCTT	540
TCCAGACTGC TGACAAATTG TACTTTGTCC TAGACTACAT TAATGGTGGA GAGTTGTTCT	600
ACCATCTCCA GAGGGAACGC TGCTTCCTGG AACCACGGGC TCGTTTCTAT GCTGCTGAAA	660
TAGCCAGTGC CTTGGGCTAC CTGCATTAC TGAACATCGT TTATAGAGAC TTAACCAG	720
AGAATATTTT GCTAGATTCA CAGGGACACA TTGTCTTAC TGACTTCGGA CTCTGCAAGG	780
AGAACATTGA ACACAACAGC ACAACATCCA CCTTCTGTGG CACGCCGGAG TATCTCGCAC	840
CTGAGGTGCT TCATAAGCAG CCTTATGACA GGAAGTGTGA CTGGTGGTGC CTGGGAGCTG	900

EP 0 887 081 A2

TCTTGTATGA GATGCTGTAT GGCCTGCCGC CTTTTTATAG CCGAAACACA GCTGAAATGT 960
 ACGACAACAT TCTGAACAAG CCTCTCCAGC TGAAACCAAA TATTACAAAT TCCGCAAGAC 1020
 5 ACCTCCTGGA GGGCCTCCTG CAGAAGGACA GGACAAAGCG GCTCGGGGCC AAGGATGACT 1080
 TCATGGAGAT TAAGAGTCAT GTCTTCTTCT CCTTAATTAA CTGGGATGAT CTCATTAATA 1140
 AGAAGATTAC TCCCCCTTTT AACCCAAATG TGAGTGGGCC CAACGAGCTA CGGCACTTTG 1200
 10 ACCCCGAGTT TACCGAAGAG CCTGTCCCA ACTCCATTGG CAAGTCCCCT GACAGCGTCC 1260
 TCGTCACAGC CAGCGTCAAG GAAGCTGCCG AGGCTTTCCT AGGGTTTTCC TATGCGCCTC 1320
 CCACGGACTC TTTCTCTGA ACCCTGTTAG GGCTTGGTTT TAAAGGATTT TATGTGTGTT 1380
 TCCGAATGTT TTAGTTAGCC TTTTGGTGA GCCGCCAGCT GACAGGACAT CTTACAAGAG 1440
 15 AATTTGCACA TCTCTGGAAG CTTAGCAATC TTATTGCACA CTGTTGCTG GAAGCTTTTT 1500
 GAAGAGCACA TTCTCCTCAG TGAGCTCATG AGGTTTTCAT TTTTCATTCT TCCTTCCAAC 1560
 GTGGTGCTAT CTCTGAAACG AGCGTTAGAG TGCCGCCTTA GACGGAGGCA GGAGTTTCGT 1620
 20 TAGAAAGCGG ACGCTGTTCT AAAAAAGTCT TCCTGCAGAT CTGTCTGGGC TGTGATGACG 1680
 AATATTATGA AATGTGCCTT TTCTGAAGAG ATTGTGTTAG CTCCAAAGCT TTTCTATCG 1740
 CAGTGTTTCA GTTCTTTATT TTCCCTGTG GATATGCTGT GTGAACCGTC GTGTGAGTGT 1800
 25 GGTATGCCTG ATCACAGATG GATTTTGTTA TAAGCATCAA TGTGACACTT GCAGGACACT 1860
 ACAACGTGGG ACATTGTTTG TTTCTTCCAT ATTTGGAAGA TAAATTTATG TGTAGACTTT 1920
 TTTGTAAGAT ACGGTTAATA ACTAAAATTT ATTGAAATGG TCTTGCAATG ACTCGTATTC 1980
 AGATGCCTAA AGAAAGCATT GCTGCTACAA ATATTTCTAT TTTTAGAAAG GGTTTTTATG 2040
 30 GACCAATGCC CCAGTTGTCA GTCAGAGCCG TTGGTGTTTT TCATTGTTTA AAATGTCACC 2100
 TGTAAATGG GCATTATTTA TGTTTTTTTT TTTGCATTCC TGATAATTGT ATGTATTGTA 2160
 TAAAGAACGT CTGTACATTG GGTTATAACA CTAGTATATT TAAACTTACA GGCTTATTG 2220
 35 TAATGTAAAC CACCATTTTA ATGTACTGTA ATTAACATGG TTATAATACG TACAATCCTT 2280
 CCCTCATCCC ATCACACAAC TTTTTTGTG TGTGATAAAC TGATTTTGGT TTGCAATAAA 2340
 ACCCTG 2346

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 431 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

EP 0 887 081 A2

Met Thr Val Lys Thr Glu Ala Ala Lys Gly Thr Leu Thr Tyr Ser Arg
1 5 10 15
5 Met Arg Gly Met Val Ala Ile Leu Ile Ala Phe Met Lys Gln Arg Arg
20 25 30
Met Gly Leu Asn Asp Phe Ile Gln Lys Ile Ala Asn Asn Ser Tyr Ala
10 35 40 45
Cys Lys His Pro Glu Val Gln Ser Ile Leu Lys Ile Ser Gln Pro Gln
50 55 60
15 Glu Pro Glu Leu Met Asn Ala Asn Pro Ser Pro Pro Pro Ser Pro Ser
65 70 80
Gln Gln Ile Asn Leu Gly Pro Ser Ser Asn Pro His Ala Lys Pro Ser
85 90 95
20 Asp Phe His Phe Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Lys Val
100 105 110
Leu Leu Ala Arg His Lys Ala Glu Glu Val Phe Tyr Ala Val Lys Val
25 115 120 125
Leu Gln Lys Lys Ala Ile Leu Lys Lys Lys Glu Glu Lys His Ile Met
130 135 140
30 Ser Glu Arg Asn Val Leu Leu Lys Asn Val Lys His Pro Phe Leu Val
145 150 155 160
Gly Leu His Phe Ser Phe Gln Thr Ala Asp Lys Leu Tyr Phe Val Leu
165 170 175
35 Asp Tyr Ile Asn Gly Gly Glu Leu Phe Tyr His Leu Gln Arg Glu Arg
180 185 190
Cys Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala Glu Ile Ala Ser
40 195 200 205
Ala Leu Gly Tyr Leu His Ser Leu Asn Ile Val Tyr Arg Asp Leu Lys
210 215 220
45 Pro Glu Asn Ile Leu Leu Asp Ser Gln Gly His Ile Val Leu Thr Asp
225 230 235 240
Phe Gly Leu Cys Lys Glu Asn Ile Glu His Asn Ser Thr Thr Ser Thr
245 250 255
50 Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu His Lys Gln
260 265 270
55 Pro Tyr Asp Arg Thr Val Asp Trp Trp Cys Leu Gly Ala Val Leu Tyr

275 280 285
 Glu Met Leu Tyr Gly Leu Pro Pro Phe Tyr Ser Arg Asn Thr Ala Glu
 5 290 295 300
 Met Tyr Asp Asn Ile Leu Asn Lys Pro Leu Gln Leu Lys Pro Asn Ile
 305 310 315 320
 10 Thr Asn Ser Ala Arg His Leu Leu Glu Gly Leu Leu Gln Lys Asp Arg
 325 330 335
 Thr Lys Arg Leu Gly Ala Lys Asp Asp Phe Met Glu Ile Lys Ser His
 340 345 350
 15 Val Phe Phe Ser Leu Ile Asn Trp Asp Asp Leu Ile Asn Lys Lys Ile
 355 360 365
 Thr Pro Pro Phe Asn Pro Asn Val Ser Gly Pro Asn Asp Leu Arg His
 20 370 375 380
 Phe Asp Pro Glu Phe Thr Glu Glu Pro Val Pro Asn Ser Ile Gly Lys
 385 390 395 400
 25 Ser Pro Asp Ser Val Leu Val Thr Ala Ser Val Lys Glu Ala Ala Glu
 405 410 415
 Ala Phe Leu Gly Phe Ser Tyr Ala Pro Pro Thr Asp Ser Phe Leu
 420 425 430
 30

Claims

1. A method for the treatment of a subject having need to inhibit activity or expression of human *sgk* polypeptide comprising:

- (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or
- (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and/or
- (c) administering to the subject a therapeutically effective amount of an antagonist that competes with said polypeptide for its ligand, substrate, or receptor.

2. A method of claim 1 in which a subject having need to inhibit activity is afflicted with chronic renal failure, diabetic nephropathy, inflammation, Alzheimers disease, and wounds.

3. A method for identifying compounds which inhibit (antagonize) or agonize the human *sgk* polypeptide which comprises:

- (a) contacting a candidate compound with cells which express the human *sgk* polypeptide (or cell membrane expressing human *sgk* polypeptide) or respond to human *sgk* polypeptide; and
- (b) observing the binding, or stimulation or inhibition of a functional response; or comparing the ability of the cells (or cell membrane) which were contacted with the candidate compounds with the same cells which were not contacted for human *sgk* polypeptide activity.

4. An antagonist identified by the method of claim 3.